Düsseldorf, 14 October 2026 – The Supervisory Board of Douglas AG today resolved to appoint Jean-Marc Bellaiche as a member of the Management Board and Chief Executive Officer (CEO) of Douglas AG with effect from 1 November 2026. The appointment is for a term of four years. Mr. Bellaiche succeeds Alexander van der Laan, who has decided to retire from active management. Mr. van der Laan will resign from his office as member and Chief Executive Officer of the Management Board by mutual agreement with the Supervisory Board with effect from 31 October 2026.
 

Change in Top Management
Jean-Marc Bellaiche to become new CEO of the DOUGLAS Group – Sander van der Laan to retire

Düsseldorf, 14 October 2026 – Jean-Marc Bellaiche will become the new Chief Executive Officer (CEO) of Europe’s leading premium beauty retailer, the DOUGLAS Group. He succeeds Sander van der Laan, who, after a career of 36 years in the international retail business including four years with the DOUGLAS Group, has decided to retire as an executive. The Supervisory Board of Douglas AG today appointed Jean-Marc Bellaiche as CEO with effect from 1 November 2026 for a term of four years.

“This important change in the leadership at the top of the company has been prepared very thoughtfully and carefully, ensuring a smooth and professional transition”, said Dr. Henning Kreke, Chairman of the Supervisory Board of the Douglas AG. “We truly regret Sander van der Laan’s decision to retire, while fully respecting his choice after a long and successful career. With his departure, the DOUGLAS Group loses an outstanding leader and highly experienced retail executive who has played a pivotal role in the successful development of the Group. At the same time, we are very pleased to have appointed Jean-Marc Bellaiche, a highly experienced executive in international retail and luxury, with a strong track record across beauty, premium department stores, digital transformation, brand building and strategy. We are convinced that he will build on the progress already made and put even more focus on customer-centricity, beauty brand partnerships and operational excellence.”

“I would like to thank the Supervisory Board of the Douglas AG for the confidence it has placed in me”, said Bellaiche. “I am particularly excited to join the Group at such an important moment in the evolution of the beauty industry. The DOUGLAS Group plays a leading role in the European premium beauty market and has a manifold of unique assets, including an outstanding omnichannel footprint, a large base of loyal customers, and an attractive assortment based on close relationships with beauty brands. I look forward to building on these strengths together with the management team and all my colleagues across 22 European countries, while driving the innovations and changes needed to succeed in a rapidly changing market environment.”

Van der Laan said: “I am incredibly grateful for my time at the DOUGLAS Group. I have met many inspiring people, learned a great deal about premium beauty, and, together with around 20,000 colleagues, we have made significant progress. The decision to step down was not an easy one for me. But after a 36-year career, including senior leadership roles at highly respected retail companies in Europe and the United States, I feel that the time is right to retire from executive management. This is the right moment to hand over the reins to someone who can bring fresh thinking and new ideas.”

The 56 year old Frenchman Bellaiche began his career at Boston Consulting Group in 1993, where he eventually became Managing Director and Global Leader of the Luxury, Fashion and Beauty sector. In 2014, he joined Tiffany & Co. as Senior Vice President and member of the Executive Committee. He subsequently held senior leadership and board positions in the technology companies Contentsquare and Arianee. After spending a decade in the United States, he moved back to Europe in 2020 to become CEO of Printemps Group, which includes the iconic French department store chain. During his five-year mandate, he strengthened Printemps’s distinctiveness and customer-centricity, introduced more exclusivities in the assortment, accelerated its international and omnichannel development, and improved the operating profitability. For the last year, he served as CEO of the luxury resort operator Sani/Ikos Group.

Sander van der Laan joined the DOUGLAS Group in October 2022. Since then, he has successfully driven the transformation of the Düsseldorf-based company into a true omnichannel business and implemented significant strategic, operational, and structural improvements. Among his key achievements are a new category and exclusive-brands strategy and a comprehensive update of the store-format and -network strategy. He also comprehensively reorganized the Group‘s supply chain, further developed the digital platforms, implemented a comprehensive ESG strategy, and harmonized internal processes and structures. In 2024, the company was listed on the stock exchange. Van der Laan has also been deeply committed to further developing the corporate culture and introduced the purpose ‘Make life more beautiful’.

Dr. Kreke said: “On behalf of the entire Supervisory Board, I would like to thank Sander van der Laan for his outstanding achievements and dedication to the company. We wish him all the best for this new chapter in his life. We also wish Jean-Marc Bellaiche a successful start in his new role at the DOUGLAS Group and look forward to working with him as he leads the company together with CFO Marco Giorgetta, the entire management team and all employees into its next phase of development.”

About the DOUGLAS Group

The DOUGLAS Group, with its commercial brands DOUGLAS, NOCIBÉ, Parfumdreams and Niche Beauty, is the number one omnichannel premium beauty destination in Europe. The DOUGLAS Group is inspiring customers to live their own kind of beauty by offering a unique assortment online and in around 1,970 stores. With unparalleled size and access to customers, the DOUGLAS Group is the partner of choice for brands and offers a premium range of selective and exclusive brands as well as own corporate brands. The assortment includes fragrances, color cosmetics, skin care, hair care, accessories as well as beauty services. Strengthening its successful omnichannel positioning while consistently developing superior customer experience is at the heart of the DOUGLAS Group strategy “Let it Bloom”. The winning business model is underpinned by the Group’s omnichannel proposition, leading brands, and data capabilities. In the financial year 2024/2025, the DOUGLAS Group generated sales of 4.58 billion euros and employed more than 19,900 people across Europe. The DOUGLAS Group (Douglas AG) is listed at the Frankfurt Stock Exchange.

For further information please visit the DOUGLAS Group Website.

Presse Contact

Peter Wübben
SVP Group Communications & Sustainability
Phone: +49 211 16847 6644
Mail: newsroom@douglas.de

Investor Contact

Dafne Sanac
Director / Senior Principal Investor Relations

Phone: +49 151 55675545
E-Mail: ir@douglas.de

Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures Q3 2026: Earnings below prior year – net sales up – forecast confirmed

Lübeck, October 14, 2026 – Based on preliminary calculations, Dräger generated earnings before interest and taxes (EBIT) of around EUR 48 million in the third quarter of 2026 (Q3 2025: EUR 56.7 million). This includes customs duty refunds of EUR 20.1 million. The EBIT margin came to around 5.6 percent (Q3 2025: 6.8 percent).

The lower net sales growth in the third quarter of 2026 was offset by a disproportionate increase in functional expenses. At the same time, the comparison base was high: In the third quarter of 2025, EBIT more than doubled due to significant net sales growth driven by catch-up effects and moderate cost development.

Net sales increased by 1.0 percent (net of currency effects; nominal: 2.1 percent) to around EUR 851 million in the third quarter of 2026 (Q3 2025: EUR 833.3 million). Net sales in the safety division rose by 4.1 percent (net of currency effects; nominal: 5.3 percent) to around EUR 381 million (Q3 2025: EUR 362.0 million). In the medical division, net sales declined by 1.4 percent (net of currency effects; nominal: -0.4 percent) to around EUR 469 million, ending slightly below the prior-year level (Q3 2025: EUR 471.3 million). The Group’s gross margin increased to around 47.5 percent (Q3 2025: 45.6 percent). The main reason for this was the customs duty refunds.

Order intake rose by 7.0 percent (net of currency effects; nominal: 8.2 percent) to around EUR 926 million (Q3 2025: EUR 856.1 million). The main growth driver was safety, with a strong increase of 20.2 percent (net of currency effects; nominal: 21.7 percent) to around EUR 452 million (Q3 2025: EUR 371.4 million). This development was due in particular to high demand in the regions Germany, Americas, and Asia-Pacific. In medical, order intake fell by 3.0 percent (net of currency effects; nominal: -2.2 percent) to around EUR 474 million (Q3 2025: EUR 484.7 million).

Business performance in the first nine months of 2026
In the first nine months, order intake of around EUR 2,674 million was 3.6 percent (net of currency effects; nominal: 3.1 percent) above the prior-year figure (9 months 2025: EUR 2,594.1 million). The safety division recorded significant growth of 13.1 percent (net of currency effects; nominal: 13.1 percent) to around EUR 1,243 million, thanks to overall very good demand (9 months 2025: EUR 1,098.6 million). In the medical division, order intake decreased by 3.5 percent (net of currency effects; nominal: -4.3 percent) to around EUR 1,431 million (9 months 2025: EUR 1,495.5 million). The main reason for this was the major order from Mexico for hospital infrastructure systems in the second quarter of 2025. Adjusted for this effect, order intake in medical would have increased slightly (net of currency effects) in the first nine months of 2026.

Net sales rose by 5.3 percent (net of currency effects; nominal: 4.7 percent) to around EUR 2,454 million (9 months 2025: EUR 2,343.5 million). Both divisions contributed to this increase: The safety division recorded growth of 6.5 percent (net of currency effects; nominal: 6.4 percent) to around EUR 1,087 million (9 months 2025: EUR 1,021.2 million), while medical recorded an increase of 4.4 percent (net of currency effects; nominal: 3.4 percent) to around EUR 1,367 million (9 months 2025: EUR 1,322.3 million). The Group’s gross margin went up to around 46.8 percent (9 months 2025: 45.1 percent).

EBIT increased by almost half to around EUR 112 million (9 months 2025: EUR 77.1 million). The EBIT margin also improved significantly to around 4.6 percent (9 months 2025: 3.3 percent). EBIT included one-off effects of EUR 27.9 million from refunded customs duties. Of this amount, EUR 7.8 million was attributable to the second quarter and EUR 20.1 million to the third quarter. Part of these refunds – EUR 3.8 million in total – relates to customs payments from the current fiscal year and is therefore recognized with no impact on earnings.

Forecast for 2026
Dräger confirms its forecast for the current fiscal year and continues to expect an increase in net sales of 2.0 to 6.0 percent (net of currency effects) and an EBIT margin of 6.0 to 8.0 percent.

The quarterly statement will be published on October 29, 2026.

 

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

 

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

 

Corporate Communications:
Ulrike Abratis
Tel. +49 451 882-3202
ulrike.abratis@draeger.com

 

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company’s knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company’s influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.

seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers
for Neurodegenerative Diseases

• Development of quantitative biomarker strategies for proteopathies through seragy’s proprietary SeRAS^® technology
• Expansion of the company’s laboratory and analytical capabilities with funding from Commerzbank, the Mittelständische Beteiligungsgesellschaft (MBG), and the State of Lower Saxony
• Separate funding from The Michael J. Fox Foundation provides support for a quantitative SeRAS-based assay for Parkinson’s disease

Hanover, Germany, October 14, 2026 – seragy holding GmbH (formerly Prosperodes GmbH), a biomarker strategy company focused on neurodegenerative diseases and other proteopathies, has secured €12 million in funding to accelerate the development of its SeRAS^® platform (Seed Replication, Analysis and Subtyping) and expand its laboratory and analytical capabilities. The financing is backed by Commerzbank, the Mittelständische Beteiligungsgesellschaft (MBG), and the State of Lower Saxony.

Proteopathies – such as Alzheimer’s, Parkinson’s, and ALS – are among the greatest challenges in modern medicine. These diseases are characterized by pathological protein aggregation and display substantial molecular heterogeneity, often with multiple distinct disease subtypes within one indication. Current technologies often lack the ability to distinguish clinically relevant molecular patterns and quantify aggregation processes with the precision required for translational drug development.

Using its proprietary SeRAS technology, seragy develops quantitative, mechanism-relevant biomarkers that generate molecular fingerprints of pathological protein aggregation from patient samples. Unlike conventional seed amplification assays, which primarily provide binary detection without molecular resolution, these fingerprints will reveal quantitative biological changes and identify relevant subtypes of proteopathies. By translating aggregation biology into actionable biomarker insights, seragy will support pharmaceutical and biotechnology partners in developing more targeted therapeutic strategies from early discovery through clinical development.

“This financing provides the foundation for us to transform how pathological protein aggregation is measured and understood,” said Dr. Thorsten Lührs, Managing Partner for Strategy & Innovation and Co-Founder of seragy. “Together with our highly qualified interdisciplinary team, we will continue advancing SeRAS as a next-generation biomarker platform that makes aggregation processes measurable and biologically interpretable. Through our global collaborations with pharmaceutical and biotechnology partners, SeRAS provides insights informing therapeutic strategies and helps accelerate the development of effective treatments for patients with proteopathies. We thank Commerzbank, the MBG, and the State of Lower Saxony for their trust and commitment to our technology.”

With this combination of debt financing, equity capital, and public funding, seragy will accelerate the further development and application of its SeRAS technology by expanding its laboratory and analytical capabilities and growing its team in Hanover. At the same time, the company will strengthen its presence in European and international markets and further expand its collaborations with pharmaceutical and biotechnology companies to provide translational biomarker strategies across early-stage discovery, preclinical, and clinical development.

“seragy combines scientific excellence and a clear vision with a highly innovative technology platform for addressing a critical challenge in developing treatments for neurodegenerative diseases,” said Marc Hülsbruch, Chairman of the Management Board for Small-Business Customers in Lower Saxony at Commerzbank AG. “By advancing cutting-edge technologies that ultimately help patients, companies like seragy demonstrate how a strong innovation ecosystem in Lower Saxony can contribute to the future of healthcare worldwide.”

Separately, seragy is one of five recipients of funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Seed Amplification Assay Innovation Program. The grant supports the development and evaluation of a quantitative biomarker assay for Parkinson’s disease and underscores the potential of the SeRAS technology to advance the development of translational biomarkers in neurodegenerative diseases.

About seragy holding GmbH

seragy holding GmbH (formerly Prosperodes GmbH) is a biomarker strategy company based in Hanover, Germany. Through its wholly owned subsidiary seragy analytics GmbH and using its proprietary SeRAS® platform, the Company develops quantitative translational biomarkers for proteopathies – diseases driven by protein aggregation – including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Seragy’s strategy is to generate molecular fingerprints of protein aggregates, which will reveal disease-specific subtypes and enable quantification of biological changes. The goal is to accelerate the development of targeted therapies through deep insights into disease mechanisms and to improve the chances of success for new drugs through precise biomarkers.

Founded in 2022 as Prosperodes GmbH, seragy holding GmbH is led by Dr. Christiane Ritter and Dr. Thorsten Lührs, two scientists with nearly three decades of expertise in protein aggregation research, alongside Arne Ungruh, an experienced business and finance leader. The holding company owns the intellectual property, acts as the licensor and consolidates central holding functions, while operational activities, particularly services and projects for partner companies, are carried out by seragy analytics GmbH. The company is supported by The Michael J. Fox Foundation, Commerzbank AG, Mittelständische Beteiligungsgesellschaft Niedersachsen (MBG), and the State of Lower Saxony, among others.

For more information, visit: https://seragy.com/

About SeRAS^®

SeRAS^® (Seed Replication, Analysis, and Subtyping) is seragy’s proprietary technology platform for the highly sensitive analysis of pathological protein aggregates. As a further development of classical seed amplification assays, SeRAS combines seeding-based biochemistry with high-sensitivity optics, automated data analysis, software algorithms, and micromechanical components. At the heart of the platform is the MetisOne^® Analyzer, which has been designed to enable quantitative and reproducible measurements of protein aggregates from patient samples. Unlike conventional seed amplification assays, which primarily provide qualitative detection, SeRAS has been developed to generate quantitative molecular fingerprints that can be used to characterize aggregation patterns, distinguish molecular subtypes, and track biological changes over the course of a disease. The platform is designed for the development of translational biomarkers, from early drug discovery through preclinical and clinical development.

 

seragy Contact: seragy holding GmbH                                                                  info@seragy.com

Media Contact: MC Services AG Dr. Cora Kaiser / Dr. Regina Lutz Tel.: +49 (0)89 210 228 0 E-Mail: seragy@mc-services.eu

Gerresheimer Improves its EcoVadis Rating and is once again awarded Gold

• Gerresheimer among the top 5% of all rated companies
• Overall score increased to 82 out of 100 points
• Ranked in the top 1% in sustainable procurement

Duesseldorf, October 14, 2026. Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, has once again been awarded Gold by the sustainability rating provider EcoVadis. EcoVadis evaluates the management systems of companies worldwide in the categories of environment, labor and human rights, ethics, and sustainable procurement. More than 175,000 companies are evaluated by EcoVadis each year. In the latest rating, Gerresheimer increased its score from 78 (2025) to 82 out of 100 points. This places Gerresheimer among the top 5% of all companies rated by EcoVadis and within the top 2% in its industry. With this rating result, Gerresheimer underscores its progress in consistently implementing its sustainability targets.

“With the improved EcoVadis rating and our first voluntary report based on the CSRD, we are making our sustainability performance measurable and transparent for our customers,” explains Wolf Lehmann, CFO of Gerresheimer AG. “We remain committed to consistently pursuing our ambitious sustainability targets in the future.”

Gerresheimer among the top 2% in its industry
Since 2011, Gerresheimer has relied on EcoVadis to have its sustainability management independently assessed across four different dimensions. In 2022, Gerresheimer achieved Gold status for the first time with a score of 68 out of 100 points and continued to improve its overall rating in the following years. In 2026, the company once again increased its score to 82 out of 100 points, placing Gerresheimer not only among the top 5% of all companies evaluated by EcoVadis but also within the top 2% in the industry. Gerresheimer performs particularly well in the area of sustainable procurement. Here, Gerresheimer ranks among the top 1% in the industry, underscoring the importance of responsible supply chains for its own sustainability performance.

Internationally recognized sustainability rating
EcoVadis’ comprehensive Corporate Social Responsibility (CSR) assessment framework is based on internationally recognized standards such as the UN Global Compact, the conventions of the International Labor Organization (ILO), the standards of the Global Reporting Initiative (GRI), the ISO 26000 standard, the CERES Principles, and the UN Guiding Principles on Business and Human Rights. The EcoVadis rating thus covers a wide range of information on companies performance in the areas of the environment, labor and human rights, ethics, and sustainable procurement, while taking industry-specific characteristics into account.

Ambitious sustainability targets
Gerresheimer has set ambitious goals to achieve measurable progress in the areas of climate protection, the circular economy, responsible supply chains, and social responsibility. With clear performance indicators, transparent reporting, and independent assessments, Gerresheimer ensures that progress is documented comprehensively and can be compared with international benchmarks.

For the 2025 financial year, Gerresheimer has, for the first time, voluntarily submitted an audited, non-financial consolidated report based on the Corporate Sustainability Reporting Directive (CSRD). In doing so, the company has significantly advanced the structure of its sustainability reporting. The report is available for download here.

In addition, Gerresheimer discloses relevant data annually on the EcoVadis platform and as part of the CDP rating. MSCI, Sustainalytics, and ISS also evaluate the company’s sustainability performance. An overview of Gerresheimer’s external sustainability assessments is available here.

 

About Gerresheimer 
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of primary packaging solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices as well as digital solutions for therapy support. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With 39 production sites in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. The Group generated revenues of around EUR 2.3bn in 2025 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
www.gerresheimer.com

Contact Gerresheimer

Media
Jutta Lorberg Group Senior Director Communication & Marketing T +49 211 6181 264 jutta.lorberg@gerresheimer.com	Dersim Korkmaz Manager Corporate Communication T +49 211 6181 296 dersim.korkmaz@gerresheimer.com
Investor Relations
Guido Pickert Vice President Investor Relations T +49 211 6181 220 gerresheimer.ir@gerresheimer.com

MindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite Launch

Multi-site program demonstrates threefold increase in rehabilitation training dose, with 84% delivered independently and significant improvements across functional measures

Geneva, Switzerland – October 14, 2026 – MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision neurotherapeutics, today announced new real-world evidence from a multi-site program conducted with Vibra Healthcare, presented yesterday at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC.

The program demonstrated that home-based rehabilitation using MindMotion increased total motor-training dose by a median factor of three compared with usual outpatient therapy alone. 84% of active training was completed independently, without direct therapist supervision. Participants also showed statistically significant improvements in functional independence, balance, mobility and cognition, alongside high patient satisfaction.

Building on previously reported inpatient results with Vibra Healthcare, the findings further support MindMaze Therapeutics’ strategy to extend high-dose, high-intensity neurorehabilitation into patients’ homes. This is particularly relevant to the Company’s upcoming launch of MindMotion Lite, expected by year-end 2026. Recently announced, the tablet-based solution is designed to deliver the full range of MindMotion GO neurotherapeutic activities with substantially reduced hardware requirements, simplifying home deployment and supporting broader adoption by healthcare providers.

“Earlier this year, we showed that MindMaze’s high-dose, high-intensity therapy, integrated into inpatient rehabilitation, delivers superior functional outcomes in a resource-efficient way,” said Zach Henderson, CEO of MindMaze Therapeutics. “Now, we are demonstrating that this value can extend into the home to address a well-recognized gap in care once patients leave the clinic, in line with the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery. These results, combined with our upcoming MindMotion Lite tablet-based solution, will help make high-quality neurotherapeutics more accessible. Together, these milestones bring us closer to our mission of making neurotherapeutics available at scale.”

Study Design and Results
The retrospective, multi-site quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with a range of neurological conditions, primarily stroke, across four Vibra Healthcare outpatient sites, without a control group. Participants followed an eight-week home-training program using MindMotion GO, with an optional four-week extension and periodic therapist supervision.

Key findings included:

• Training dose: Patients completed an average of 174 minutes of active training per week, with 84.4% delivered asynchronously. The additional home training increased total motor-training dose by a median factor of 3.0 compared with usual outpatient therapy alone, based on published assumptions for active practice during usual care.
• Feasibility and engagement: 92.7% successfully completed home setup, while 80.2% achieved the predefined minimum training exposure. Among surveyed participants, 83.8% of satisfaction ratings were positive.
• Functional outcomes: Statistically significant pre–post improvements were observed in independence (Barthel Index: +10.4 points), balance (Berg Balance Scale: +10.5 points), cognition (SLUMS: +3.4 points) and mobility (Timed Up and Go: −8.8 seconds) among participants with available paired assessments.

The full poster, High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program, is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence.

About MindMaze Therapeutics
MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable, precision neurotherapeutics, dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company’s FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other neurological disorders. With an extensive library of rigorous clinical validation, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine. For more information, visit www.mindmazetherapeutics.com.

Media & Investor Contacts
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance
 

Hamburg, Germany – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for first nine months of 2026. Full financial results for the third quarter and the first nine months of 2026 will be published on November 5, 2026, as scheduled.

Based on preliminary figures, Evotec expects Group revenues for the first nine months of 2026 of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million. These figures are above current market expectations, with the variance driven largely by the phasing of consensus estimates.

Evotec reaffirms its full-year 2026 guidance, which projects Group revenues of approximately €570 to €610 million (€595 to €635 million at CER) and adjusted Group EBITDA of approximately -€70 to -€105 million (-€60 to -€90 million at CER).
 

– End of the ad hoc release –
 

Contact: Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 7068 8784 (m), sarah.fakih@evotec.com

Berlin/Breda, 13 October 2026. Eckert & Ziegler Brazil, a regional subsidiary of the global nuclear medicine group Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), and TerThera announced today the signing of a strategic supply agreement for the precursor Terbium-161.

Under the terms of the agreement, TerThera will supply its GMP-compliant non-carrier-added (n.c.a.) Terbium-161 (Tb-161) to Eckert & Ziegler Brazil. This partnership establishes a critical and reliable supply chain for the innovative isotope in South America, directly providing Brazilian patients access to the next generation of radioligand therapies. Moreover, the availability of GMP-grade Tb-161 will allow local pharmaceutical developers and clinical institutions to investigate the combination of Tb-161 with novel peptides, antibodies, and FAP-inhibitors to target a broad spectrum of oncological indications. The agreement, between Eckert & Ziegler Brazil and TerThera, will bring the next generation of Radioligand Therapy (RLT) to Brazil and allow access to a novel radiopharmaceutical for cancer healthcare.

Terbium-161, a carrier free lanthanide produced by neutron activation, is a highly promising radionuclide for Radioligand Therapy (RLT) exhibiting comparable chemical characteristics to known radiolanthanides that has the potential, due to highest addition of Auger electronic emission with a higher linear energy transfer, to improve anti-tumor capabilities for primary and (micro)metastasized cancers. The latest clinical results have shown a promising and effective anti-tumor response, even after treatment stops of conventional medicine, providing for a new therapy option by depositing a highest but localized tumor dose with limited impact on healthy tissue.

Expanding Local Theranostic Infrastructure

“It is a great milestone that after six years of absence we are back in Brazil with a potentially better radionuclide,” said Philippe van Overeem, CEO of TerThera. “Having supplied Lutetium-177 to Brazil for almost two decades, I know firsthand the passion and capability of the local nuclear medicine community. Returning to this market with GMP-grade Terbium-161 allows us to build on that legacy and give Brazilian doctors and researchers a powerful, next-generation tool to treat micro-metastases and complex tumors more effectively.”

The agreement leverages Eckert & Ziegler’s robust presence in Latin America, combining TerThera’s unique isotope production capabilities with a powerful regional distribution and manufacturing network.

“We are proud to partner with TerThera to bring this highly promising isotope to South America,” stated Fabrício Diel, the Managing Director of Eckert & Ziegler Brazil. “Integrating Terbium-161 into our portfolio perfectly aligns with our mission of “Contributing to saving lives” and our goal to expand local access to strategic theranostic solutions. By combining this premium radionuclide with advanced targeting agents here in Brazil, we are shortening the supply chain and opening new clinical horizons for oncology patients across the region.”

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,100 employees, is THE leading independent radioisotope supplier and a specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
www.ezag.com

About TerThera BV
TerThera is a radionuclide production focused company based in The Netherlands. The founders and the staff of TerThera have decades of experience in the nuclear medicine industry and are giving their full focus on the production of the innovative radionuclide Terbium-161 (Tb-161). TerThera is building a global platform to meet the growing demand for radionuclides in oncology and nuclear medicine.
www.terthera.com

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 

PL BioScience Launches PL Synergy to Simplify and Standardize MSC Research

Two-component culture kit combines PL Base and PL Boost for streamlined xeno-free MSC expansion.

Aachen, Germany, 13 October 2026 – PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion and development, today announced the launch of PL Synergy, a research-grade culture kit designed to simplify and standardize the expansion of Mesenchymal Stromal Cells (MSCs) in academic and translational research.

PL Synergy combines two components optimized for joint use: PL Base, a custom-formulated basal medium developed for MSC growth and proliferation, and PL Boost, a proprietary supplement that eliminates the need for Fetal Bovine Serum (FBS). The two-component system requires no additional preparation and provides researchers with a streamlined, optimized MSC culture workflow.

By removing the need for performance and compatibility assessment of independent media and supplements, PL Synergy is designed to simplify laboratory protocols while reducing the lot-to-lot variability associated with animal-derived serum. The xeno-free system is enhanced for MSC viability and kinetics compared with standard α-MEM + FBS formulations, supporting more consistent and reproducible research workflows.

“MSC researchers need culture workflows that combine performance with consistency and ease of use,” said Dr. Hatim Hemeda, CEO of PL BioScience. “PL Synergy brings together two components designed to work as one system, reducing the burden associated with technical validation, while providing researchers with a straightforward, xeno-free option for MSC expansion. With this launch, we are expanding the tools available to academic and translational researchers working to generate more reliable and reproducible results by using a single, optimized system.”

PL Synergy is intended for academic research laboratories conducting MSC studies, biotechnology companies developing cell culture models for mechanistic research or drug screening, and regenerative medicine researchers working in early and pre-clinical research. The kit is supplied jointly as PL Base and PL Boost and is intended for Research Use Only.

For more information about PL Synergy and its potential to support streamlined MSC research workflows, meet the PL BioScience team at BIO-EUROPE Cologne, on November 9-11, at the BIO.NRW booth (8-50). We look forward to discussing this latest innovation and exploring opportunities for collaboration.

 

About PL BioScience:

PL BioScience GmbH, a life science company located in Aachen, Germany, specializes in the production and development of Human Platelet Lysate (HPL). The company has pioneered proprietary technology to produce fully artificial HPL, allowing for a fully lab-made, scalable supply of HPL. PL BioScience currently offers a comprehensive portfolio of donor-derived, natural HPL products tailored for a range of applications – the ELAREM™platform. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. The company’s latest addition, PL Synergy, is a research-grade, xeno-free two-component culture kit — combining PL Base basal medium with the PL Boost supplement pack — designed to simplify Mesenchymal Stromal Cell expansion workflows and support MSC viability and proliferation without the need for FBS. PL BioScience is the only company worldwide holding a patent for the gamma-irradiation of HPL, covering the manufacturing process for ELAREM™ Ultimate-FD PLUS.

For more information on PL BioScience and the ELAREM™ platform, visit: https://www.pl-bioscience.com/

About Human Platelet Lysate:

Human Platelet Lysate (HPL) is an innovative, human-derived cell culture supplement used to support the growth and expansion of cells in research and clinical development, particularly in cell therapy, stem cell, and regenerative medicine applications. It is produced from donated human blood platelets that are no longer suitable for transfusion and would otherwise be discarded – making it a sustainable and resource-efficient alternative to traditional cell culture supplements.

In cell culture, HPL provides essential growth factors and nutrients that promote healthy, robust cell proliferation. Compared to conventional products such as Fetal Bovine Serum (FBS), which is harvested from unborn calves, HPL delivers more consistent results in cell growth, is free from animal-derived pathogens, and aligns with the increasing demand for animal-free and ethically responsible laboratory practices.

ELAREM™, PL BioScience’s line of xeno-free HPL products, can be used from early-stage research to the production of cell-based therapies under Good Manufacturing Practice (GMP) conditions for the treatment of patients.

Contact:

Dr. Hatim Hemeda, CEO
PL BioScience GmbH
+49(0)24195719-100
info@pl-bioscience.com

Media contact:
MC Services AG
Raimund Gabriel, Dr. Regina Lutz
+49 (0)89 210 228 0

U.S.: Catherine Featherston
+1-203-444-4393
E-Mail: pl-bioscience@mc-services.eu